Abstract
Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1. Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Tumor Suppressor DLC-1: Far From Clear
Volume: 17 Issue: 7
Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Abstract: Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1. Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.Export Options
About this article
Cite this article as:
Liu Xu, Pan Yao-Jie, Zheng Jun-Nian*, Pei Dong-Sheng*, The Role of Tumor Suppressor DLC-1: Far From Clear, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160907142754
DOI https://dx.doi.org/10.2174/1871520616666160907142754 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs
Mini-Reviews in Medicinal Chemistry Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
Recent Patents on Anti-Infective Drug Discovery Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
Current Cancer Drug Targets ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Protein Engineering: A New Frontier for Biological Therapeutics
Current Drug Metabolism Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients
Current Genomics